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ABSTRACT
Objective: To compare effects of natalizumab on inflammatory and regulatory T cells with regard
to expression of a4-integrin (CD49d).
Methods: Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple
sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8
healthy controls were included. The positive rate of CD49d was analyzed and compared among
T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d1Th1, CD49d1Th17,
and CD49d1Treg, respectively).
Results: Natalizumab treatment increased CD49d ratios, CD49d1Th1/CD49d1Treg, and
CD49d1Th17/CD49d1Treg. This indicates larger reduction of the CD49d1 population in Treg
cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exacerbation
during natalizumab treatment were remarkably higher than those of the other natalizumab-
treated patients. Natalizumab treatment increased the expression of TBX21, RORC, interferon
(IFN)–g, and interleukin (IL)–17A, and decreased the expression of FOXP3 in CD49d1 memory
CD4 T cells. Natalizumab treatment also increased the amount of IFN-g and IL-17A secreted by
CD49d1 memory CD4 T cells.
Conclusions: The reduction rate of the CD49d1 population in Treg cells was larger than that in
Th1 or Th17 cells. Although the large reduction in CD49d1 population is beneficial for MS, the
proinflammatory state of residual CD49d1 cells might, in part, explain the presence of disease
activity under natalizumab treatment. Neurol Neuroimmunol Neuroinflamm 2016;3:e210; doi:
10.1212/NXI.0000000000000210
GLOSSARY
HC 5 healthy controls; IFN 5 interferon; IgG 5 immunoglobulin G; IL 5 interleukin; mAb 5 monoclonal antibodies; mCD4 5
memory CD4; mRNA 5 messenger RNA; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis
optica spectrum disorder; PBMC 5 peripheral blood mononuclear cell; Th1 5 T helper 1; Th17 5 T helper 17; Treg 5
regulatory T; VCAM-1 5 vascular cell adhesion molecule–1.
Natalizumab is a humanized monoclonal antibody against a4-integrin (CD49d) that is approved
for the treatment of multiple sclerosis (MS). It decreases CD49d expression on circulating
lymphocytes and blocks their interaction with vascular cell adhesion molecule–1 (VCAM-1)
and fibronectin expressed by vascular endothelial cells. CD49d is the main adhesion molecule
involved in lymphocyte migration to the CNS. Therefore, blocking this interaction leads to
decreased number of inflammatory lymphocytes with migratory capacity into the CNS.1,2
A clinical trial showed a remarkable reduction in annual relapse rate by natalizumab treat-
ment. More than one third of natalizumab-treated patients achieved complete remission with-
out clinical or radiologic activity.3 Nevertheless, some natalizumab-treated patients experience a
clinical relapse or worsening of the Expanded Disability Status Scale.4
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CD49d is expressed not only by inflamma-
tory but also by regulatory CD4 T cells.
Although natalizumab is supposed to decrease
the expression of CD49d on both T-cell sub-
sets, differences in effects on each subset
remain unclear.
In this study, we show that natalizumab de-
creases the CD49d1 population more signif-
icantly in regulatory than in inflammatory
CD4 T cells. The balance between inflamma-
tory and regulatory CD4 T cells was highly
disrupted in 2 patients who experienced exac-
erbation under natalizumab treatment.
Although the large reduction in inflammatory
T cells with migratory capacity is beneficial for
MS, the disrupted balance may contribute to
disease activity during natalizumab treatment.
METHODS Participants. Twenty-seven natalizumab-naive
and 8 natalizumab-treated patients with MS, 7 patients with
neuromyelitis optica (NMO) or NMO spectrum disorder
(NMOSD), and 8 healthy controls (HC) were examined. The
patient profile was similar between natalizumab-naive and
natalizumab-treated MS groups: mean age was 42.5 (range 19–
67) and 37.8 (range 33–48) years; ratio of male to female patients
was 7/20 and 4/4; ratio of relapsing-remitting MS to secondary
progressive MS patients was 18/9 and 5/3; disease duration was
11.0 6 16.2 and 11.8 6 7.9 (mean 6 2 SD) years; and annual
relapse rate in the year just before the analysis was 0.486 1.4 and
1.0 6 2.1 (mean 6 2 SD), respectively. All natalizumab-treated
patients had occasional disease exacerbations before the start of
natalizumab. All natalizumab-treated patients had received more
than 3 doses of natalizumab at the time of analysis. Blood samples
were obtained just before the infusion of natalizumab. The
diagnoses of MS, NMO, and NMOSD were established
according to McDonald and Wingerchuk criteria.5–7
Standard protocol approvals, registrations, and patient
consents. This study was approved by the Ethical Committee of
the National Institute of Neuroscience and written informed con-
sent was obtained from all participants. This is a cross-sectional
study conducted between October 2014 and July 2015 at
National Institute of Neuroscience, Japan.
Cell preparation and flow cytometry. Fresh peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient
centrifugation, using Ficoll-Paque PLUS (GE Healthcare
Bioscience, Mississauga, Canada). They were stained against
cell surface antigens, followed by intracellular staining of
transcription factors using Foxp3/transcription factor
staining buffer set (eBiosciences, San Diego, CA) according
to the manufacturer’s instructions. The fluorescent-
conjugated monoclonal antibodies (mAb) and isotype
controls used in this study were as follows: PE-Cy7-anti-
CD3, PerCp-Cy5.5-anti-CD4, BV421-anti-CD127, and
BV421-mouse immunoglobulin G (IgG) 1k (BioLegend, San
Diego, CA); FITC-anti-Foxp3, PE-anti-RORgt, eFluor
660-anti-T-bet, FITC-rat IgG2ak, PE-rat IgG2ak, and
eFluor 660-mouse IgG1k (eBiosciences); and APC-H7-anti-
CD45RA, BV510-anti-CD49d, and BV510-mouse IgG1k
(BD Biosciences, San Jose, CA). The cells were analyzed by a
FACS Canto II flow cytometer (BD Biosciences) with FlowJo
software (Tree Star, Ashland, OR).
Cell culture. To analyze cytokine production from CD49d-
positive and CD49d-negative memory CD4 T cells in vitro,
each population was isolated from PBMC using a FACS Aria II
cell sorter (BD Biosciences). Ninety-six-well flat-bottom plates
were coated with 2 mg/mL anti-CD3 mAb (OKT3) and 4 mg/
mL anti-CD28 mAb (Beckman Coulter, Brea, CA) for 1 hour at
37°C. Isolated cells were cultured in the coated plates at 5 3 104
cells per well with AIM V medium (Life Technologies, Carlsbad,
CA) for 72 hours. The amount of cytokines in the supernatant
was measured using ELISA kits (interferon [IFN]–g, interleukin
[IL]–10, GM-CSF: BD Biosciences; interleukin [IL]–17A: R&D
Systems, Minneapolis, MN). Cell culture was performed in
triplicate for each sample.
Quantification of messenger RNA (mRNA). Total RNA
was prepared from the sorted cells using RNeasy Kit and
RNase-Free DNase Set (QIAGEN, Germantown, MD), and
reverse transcribed to complementary DNA using PrimeScript
RT Master Mix (Takara Bio, Shiga, Japan). PCR was
performed using SYBR Premix Ex Taq (Takara Bio) on
LightCycler 96 (Roche, Basel, Switzerland). The expression
level of each mRNA was determined with normalization to
b-actin. The following primers were used: IFN-g-forward,
GCAGGTCATTCAGATGTAGCGG, and IFN-g-reverse,
TGTCTTCCTTGATGGTCTCCACAC; IL-17A-forward, CA
ACCGATCCACCTCACCTT, and IL-17A-reverse, GGCAC
TTTGCCTCCCAGAT; CSF2-forward, CCATGATGGCCA
GCCACTAC, and CSF2-reverse, CTGGCTCCCAGCAGTC
AAAG; IL-10-forward, CCGTGGAGCAGGTGAAGAATG,
and IL-10-reverse, AGTCGCCACCCTGATGTCTC; TBX21-






Data analysis and statistics. Data were analyzed with FlowJo
software (Tree Star) and Prism software (GraphPad Software, San
Diego, CA). Unpaired t test or Mann-WhitneyU test was used to
compare data from 2 groups, as appropriate. Kruskal-Wallis test
with Dunn multiple comparison test was used to compare data
from more than 2 groups. The difference was considered
significant when p value was ,0.05.
RESULTS Natalizumab reduces the CD49d-positive
population especially in regulatory T cells. To clarify dif-
ferences in effects of natalizumab on inflammatory
and regulatory T cells, T-cell subsets were defined
by flow cytometry. After memory CD4 (mCD4)
T cells were identified as CD31CD41CD45RA2
lymphocytes, T helper 1 (Th1), T helper 17 (Th17),
and regulatory T (Treg) cells were defined according
to the expression of transcription factors, Tbet,
RORgt, and Foxp3, respectively (figure 1A). The
CD49d-positive population was assessed in each
T-cell subset. The frequency of Th1, Th17, and
Treg cells in mCD4 T cells was similar among
patient subgroups (natalizumab-naive MS,
natalizumab-treated MS, NMO/NMOSD, and HC)
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(figure 1B). The expression of CD49d was higher in
Th1 and Th17 cells than in Treg cells and was reduced
in all subsets with natalizumab treatment (figure 1, A
and C). Unexpectedly, natalizumab reduced the
CD49d1 population especially in regulatory T cells.
The ratio of CD49d positivity of Th1 cells to that of
Figure 1 Natalizumab induces larger reduction of CD49d1 population in regulatory T (Treg) than in T helper 1 (Th1) or T helper 17 (Th17) cells
(A) Representative dot plot and histogram by flow cytometry. CD31CD41CD45RA2mCD4T cells were divided into Th1, Th17, and Treg cells based on the
expression of each characteristic transcription factor. The CD49d1 population was defined based on the fluorescence intensity of isotype control. (B)
Frequencies of Th1, Th17, and Treg cells amongmemory CD4 (mCD4) T cells. (C) CD49d1 population among mCD4 T, Th1, Th17, and Treg cells. (D) Ratio of
CD49d-positive rate of inflammatory cells to that of Treg cells (CD49d1Th1/CD49d1Treg, CD49d1Th17/CD49d1Treg). (E) Ratio of CD49d-negative rate
of inflammatory cells to that of Treg cells (CD49d-Th1/CD49d-Treg, CD49d-Th17/CD49d-Treg). (F) Ratios (as described in D) of natalizumab-treated
patients during remission and during relapse. Kruskal-Wallis test with Dunn multiple comparison test was used in B, C, D, and E. Statistical data were
described only between MS and MS 1 natalizumab groups in C and D. Unpaired t test was used in F. Error bars represent the mean 6 SD. *p , 0.05, **p ,
0.01, ***p , 0.001. NC 5 healthy controls; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica.
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Treg cells (CD49d1Th1/CD49d1Treg) was
significantly higher in natalizumab-treated patients
than in the other patients with MS.
CD49d1Th17/CD49d1Treg was also significantly
higher in natalizumab-treated patients (figure 1D).
As CD49d1 T cells are considered to have
migratory capacity into the CNS, this result indicates
a disrupted balance between inflammatory and
regulatory CD4 T cells in the CNS. The CD49d
ratios were not different among natalizumab-naive
MS, NMO/NMOSD, and HC. In contrast, the
ratios of CD49d negativity of inflammatory T cells
to that of regulatory T cells (CD49d-Th1/CD49d-
Treg and CD49-Th17/CD49d-Treg) were not
different among patient subgroups. They were much
lower than the CD49d-positive counterparts
(CD49d1Th1/CD49d1Treg and CD49d1Th17/
CD49d1Treg, respectively) (figure 1E). This
suggests the predominance of inflammatory T cells
in the CD49d1 population irrespective of disease or
treatment.
Among patients treated with natalizumab, 2 pa-
tients experienced clinical exacerbation confirmed
by MRI. Symptoms started within 4 weeks after the
final administration of natalizumab in both cases.
The CD49d ratios, CD49d1Th1/CD49d1Treg
and CD49d1Th17/CD49d1Treg, were significantly
higher in these patients than in the other patients under
natalizumab treatment (figure 1F). Moreover, the ratios
were analyzed repeatedly in one of the exacerbated pa-
tients and were found to be lower during remission.
CD49d1Th1/CD49d1Treg and CD49d1Th17/
CD49d1Treg decreased from 9.08 and 7.23 during
exacerbation to 4.67 and 6.78 during remission, respec-
tively. This further supports the clinical importance of
the ratios that reflect the balance between inflammatory
and regulatory CD4 T cells with migratory capacity.
Natalizumab enhances the expression of inflammatory
genes and reduces the expression of regulatory genes in
CD49d1 mCD4 T cells. To evaluate the in vivo status
of CD49d1 mCD4 T cells, the expression of genes
associated with inflammatory and regulatory T cells
was measured by quantitative real-time PCR. The
expression of mRNA was normalized to that of
endogenous b-actin for each sample. Natalizumab
enhanced the expressions of proinflammatory genes
(TBX21, RORC, IFN-g, and IL-17A) and reduced
the expression of FOXP3 in CD49d1mCD4 T cells
(figure 2A). Although not significant, the expression
of IL-10 tended to be reduced by natalizumab
treatment. This is consistent with results of flow
cytometry, which indicates disrupted balance
between inflammatory and regulatory function
under natalizumab treatment. Additionally, the
expressions of TBX21, IFN-g, and IL-17A were
higher and that of FOXP3 was lower in CD49d1
mCD4 T cells than in CD49d2 mCD4 T cells
(figure 2A). This is also consistent with the flow
cytometry data, which suggests predominance of
inflammatory mCD4 T cells among the CD49d1
population irrespective of treatment.
Natalizumab increases the secretion of IFN-g and IL-17A
by CD49d1 mCD4 T cells. Finally, the in vitro func-
tion of CD49d1mCD4 T cells was evaluated. Those
cells were isolated from natalizumab-naive and
natalizumab-treated patients, and were cultured
under stimulation of anti-CD3 and anti-CD28
mAbs. The amount of IFN-g and IL-17A in the
supernatant was higher in the cell culture from
natalizumab-treated patients than in that from
natalizumab-naive patients (figure 2B). These data
suggest that natalizumab enhances inflammatory
function in mCD4 T cells with migratory capacity
into the CNS. The amount of IFN-g and IL-17A was
higher in CD49d1 than in CD49d2mCD4 T cells.
This again suggests predominance of inflammatory
function among the CD49d1 population.
DISCUSSION CD49d plays a key role in the pathol-
ogy of MS. CD49d on inflammatory T cells binds
VCAM-1 and fibronectin on vascular endothelial
cells, which causes T-cell migration into the CNS.1
It has been demonstrated that CD49dhigh
encephalitogenic Th1 cells migrate into the brain
parenchyma in experimental autoimmune
encephalomyelitis, a disease model of MS. In
contrast, CD49dlow nonencephalitogenic Th1 cells
do not enter the brain parenchyma.8 In MS,
CD49dhigh T cells are abundant in the CSF
compared to peripheral blood.9 It is supposed that
there is an absolute threshold for CD49d on the
cell surface that is required for cells to migrate
across blood barriers.1 Besides, CD49dhigh mCD4
T cells have proinflammatory function and are
associated with relapses in MS.10 As is consistent
with these previous reports, our data showed higher
expression of proinflammatory genes (TBX21,
IFN-g, and IL-17A) and cytokines (IFN-g and
IL-17A) and lower expression of a regulatory gene
(FOXP3) in CD49d1 mCD4 T cells than in
CD49d2 mCD4 T cells.
Natalizumab is considered to exert its effect by
downregulating CD49d on circulating lymphocytes,
which in turn inhibits their adhesion to endothelial
cells and migration into the CNS.11 Natalizumab
binds CD49d on the surface of lymphocytes.
CD49d is then internalized and degraded within a
few hours.12 CD49d expression on circulating lym-
phocytes is largely decreased by natalizumab treat-
ment even after the first infusion.13 The reduction
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rate of the CD49d1 population is known to differ
between cell subsets, such as T cells, B cells, and
monocytes.14 This varied expression of CD49d is
considered to explain different capacities of migration
of various types of cells under natalizumab treat-
ment.15 However, differences in effects of natalizu-
mab remain unclear between inflammatory and
regulatory T-cell subsets. Although it has been shown
that natalizumab increases the frequency of IFN-g1,
IL-171, and Tbet1 subsets among total CD4
T cells, the expression of CD49d has not yet been
determined in these populations.12,16,17
This study was designed to clarify differences in ef-
fects of natalizumab on inflammatory and regulatory
T cells and the phenotype of CD49d1 T cells under
natalizumab treatment. It was shown that natalizu-
mab disrupts the balance between inflammatory and
regulatory T cells in the CD49d1 population, which
is considered to have migratory capacity. Two ratios
comparing CD49d positivity of inflammatory T cells
to that of regulatory T cells, CD49d1Th1/
CD49d1Treg and CD49d1Th17/CD49d1Treg,
were used here to represent the balance. These ratios
were shown to be significantly higher in natalizumab-
treated patients, as described. Moreover, natalizumab
increased expression of genes associated with inflam-
matory T cells (TBX21, RORC, IFN-g, and IL-17A)
and decreased expression of FOXP3 in CD49d1
mCD4 T cells. Natalizumab also increased the
amount of inflammatory cytokines (IFN-g and
IL-17A) secreted by CD49d1 mCD4 T cells. These
results indicate that natalizumab enhances inflamma-
tory function among T cells with migratory capacity
into the CNS.
Furthermore, the 2 ratios, CD49d1Th1/
CD49d1Treg and CD49d1Th17/CD49d1Treg,
were correlated with disease activity during natali-
zumab treatment. Two exacerbated patients had
significantly higher ratios compared to the other
natalizumab-treated patients. These ratios were
Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d1 memory
CD4 cells
(A) Relative expressions of messenger RNA (mRNA) associated with inflammatory and regulatory T cells. The expression
level of each mRNA was determined with normalization to b-actin; n 5 7 for each group. (B) Amount of cytokines secreted
by each population under stimulation with anti-CD3 monoclonal antibodies (mAb) and anti-CD28 mAb. Cell culture was
performed in triplicate for each sample. Multiple sclerosis (MS): n 5 5; MS 1 natalizumab: n 5 4. Mann-Whitney U test was
used. Error bars represent the mean 6 SD. *p , 0.05, **p , 0.01, ***p , 0.001. IFN 5 interferon; IL 5 interleukin.
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analyzed at another time point during remission in
one of these exacerbated patients and were shown
to be reduced. This suggests the clinical importance
of these ratios under natalizumab treatment.
Circulating natalizumab binds residual CD49d on
the surface of lymphocytes. However, CD49d is not
saturated with natalizumab in vivo. The saturation
level is supposed to be approximately 60%–100%,
which decreases gradually after the infusion of nata-
lizumab.18–20 Although CD49d measured in our
study might not have been fully functional, a certain
fraction of CD49d is considered not bound by nata-
lizumab on any CD49d1 lymphocyte. Most impor-
tantly, the CD49d ratios based on the residual
CD49d expression are shown to have clinical rele-
vance, as discussed above.
It has been reported that antibodies against nata-
lizumab are associated with low serum concentration
of natalizumab and are also associated with relapses
and gadolinium-enhancing lesions observed on
MRI.21 The presence of neutralizing antibodies is
indeed considered as a cause for some patients being
poor responders. Although neutralizing antibodies
were not measured in our study, similar or lower
expression of CD49d expression by mCD4 T cells
in the 2 exacerbated patients (16.8% and 32.3%)
than in the other patients suggests that there was
sufficient natalizumab in the sera of the 2 patients.
CD49d expression is known to be a reliable marker
of the presence of neutralizing antibodies and nata-
lizumab concentration.13,21
The lack of longitudinal data including before and
after natalizumab treatment is a limitation of this
study.
Our study showed that natalizumab enhances
proinflammatory function among CD49d1 mCD4
T cells, which are considered to have migratory capac-
ity. The absolute number of CD49d1 cells is largely
reduced by natalizumab treatment. Although this is
beneficial for MS, the disrupted function might, in
part, explain the presence of disease activity during
natalizumab treatment. The CD49d ratios described
here are candidate biomarkers to monitor patients
treated with natalizumab. Further replication on an
independent cohort would be needed to establish
these findings.
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